Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer

NCT06818773 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Biliary Tract Cancer
HER2 Positive

Interventions

DRUG: Inetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor

Sponsor

Eastern Hepatobiliary Surgery Hospital